APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Coagulation Factor II Monoclonal Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Coagulation Factor II Monoclonal Antibody Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchCoagulation Factor II Monoclonal Antibody Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Coagulation Factor II Monoclonal Antibody Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Coagulation Factor II Monoclonal Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Coagulation Factor II Monoclonal Antibody Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Coagulation Factor II Monoclonal Antibody Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Coagulation Factor II Monoclonal Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Coagulation Factor II Monoclonal Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Coagulation Factor II Monoclonal Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Coagulation Factor II Monoclonal Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Coagulation Factor II Monoclonal Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Coagulation Factor II Monoclonal Antibody market include ​​Abcam, Abbexa, Arigo Biolaboratories Corp., Assay Genie, Biorbyt, Bio-Techne, Cell Signaling Technology, Inc., Creative Biolabs and GeneTex, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Coagulation Factor II Monoclonal Antibody market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Coagulation Factor II Monoclonal Antibody and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Coagulation Factor II Monoclonal Antibody sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Coagulation Factor II Monoclonal Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.

Coagulation Factor II Monoclonal Antibody Segment by Company

​​Abcam

Abbexa

Arigo Biolaboratories Corp.

Assay Genie

Biorbyt

Bio-Techne

Cell Signaling Technology, Inc.

Creative Biolabs

GeneTex

LifeSpan BioSciences, Inc

MyBiosource, Inc.

OriGene Technologies, Inc.

RayBiotech, Inc.

Coagulation Factor II Monoclonal Antibody Segment by Type

Recombinant

Non-recombinant

Coagulation Factor II Monoclonal Antibody Segment by Application

Immunofluorescence

Immunoprecipitation

ELISA

Flow Cytometry

Western Blot

Other

Coagulation Factor II Monoclonal Antibody Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Coagulation Factor II Monoclonal Antibody status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Coagulation Factor II Monoclonal Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Coagulation Factor II Monoclonal Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze Coagulation Factor II Monoclonal Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Coagulation Factor II Monoclonal Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Coagulation Factor II Monoclonal Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Coagulation Factor II Monoclonal Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Coagulation Factor II Monoclonal Antibody market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Coagulation Factor II Monoclonal Antibody industry.

Chapter 3: Detailed analysis of Coagulation Factor II Monoclonal Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Coagulation Factor II Monoclonal Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Coagulation Factor II Monoclonal Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Coagulation Factor II Monoclonal Antibody Industry Trends Table 2. Coagulation Factor II Monoclonal Antibody Industry Drivers Table 3. Coagulation Factor II Monoclonal Antibody Industry Opportunities and Challenges Table 4. Coagulation Factor II Monoclonal Antibody Industry Restraints Table 5. Global Coagulation Factor II Monoclonal Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Coagulation Factor II Monoclonal Antibody Revenue Share by Company (2021-2026) Table 7. Global Coagulation Factor II Monoclonal Antibody Sales Volume by Company (k units) & (2021-2026) Table 8. Global Coagulation Factor II Monoclonal Antibody Sales Volume Share by Company (2021-2026) Table 9. Global Coagulation Factor II Monoclonal Antibody Average Price (US$/unit) of Company (2021-2026) Table 10. Global Coagulation Factor II Monoclonal Antibody Company Ranking, (2024-2026) & (USD Million) Table 11. Global Coagulation Factor II Monoclonal Antibody Key Company Manufacturing Base & Headquarters Table 12. Global Coagulation Factor II Monoclonal Antibody Company, Product Type & Application Table 13. Global Coagulation Factor II Monoclonal Antibody Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Coagulation Factor II Monoclonal Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Recombinant Table 18. Significant Companies of Non-recombinant Table 19. Global Coagulation Factor II Monoclonal Antibody Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Coagulation Factor II Monoclonal Antibody Sales Volume by Type (2021-2026) & (k units) Table 21. Global Coagulation Factor II Monoclonal Antibody Sales Volume by Type (2027-2032) & (k units) Table 22. Global Coagulation Factor II Monoclonal Antibody Sales Volume Share by Type (2021-2026) Table 23. Global Coagulation Factor II Monoclonal Antibody Sales Volume Share by Type (2027-2032) Table 24. Global Coagulation Factor II Monoclonal Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Coagulation Factor II Monoclonal Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Coagulation Factor II Monoclonal Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Coagulation Factor II Monoclonal Antibody Sales Value Share by Type (2021-2026) Table 28. Global Coagulation Factor II Monoclonal Antibody Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Immunofluorescence Table 30. Significant Companies of Immunoprecipitation Table 31. Significant Companies of ELISA Table 32. Significant Companies of Flow Cytometry Table 33. Significant Companies of Western Blot Table 34. Significant Companies of Other Table 35. Global Coagulation Factor II Monoclonal Antibody Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Coagulation Factor II Monoclonal Antibody Sales Volume by Application (2021-2026) & (k units) Table 37. Global Coagulation Factor II Monoclonal Antibody Sales Volume by Application (2027-2032) & (k units) Table 38. Global Coagulation Factor II Monoclonal Antibody Sales Volume Share by Application (2021-2026) Table 39. Global Coagulation Factor II Monoclonal Antibody Sales Volume Share by Application (2027-2032) Table 40. Global Coagulation Factor II Monoclonal Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Coagulation Factor II Monoclonal Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Coagulation Factor II Monoclonal Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Coagulation Factor II Monoclonal Antibody Sales Value Share by Application (2021-2026) Table 44. Global Coagulation Factor II Monoclonal Antibody Sales Value Share by Application (2027-2032) Table 45. Global Coagulation Factor II Monoclonal Antibody Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Coagulation Factor II Monoclonal Antibody Sales by Region (2021-2026) & (k units) Table 47. Global Coagulation Factor II Monoclonal Antibody Sales Market Share by Region (2021-2026) Table 48. Global Coagulation Factor II Monoclonal Antibody Sales by Region (2027-2032) & (k units) Table 49. Global Coagulation Factor II Monoclonal Antibody Sales Market Share by Region (2027-2032) Table 50. Global Coagulation Factor II Monoclonal Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Coagulation Factor II Monoclonal Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Coagulation Factor II Monoclonal Antibody Sales Value Share by Region (2021-2026) Table 53. Global Coagulation Factor II Monoclonal Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Coagulation Factor II Monoclonal Antibody Sales Value Share by Region (2027-2032) Table 55. Global Coagulation Factor II Monoclonal Antibody Market Average Price (US$/unit) by Region (2021-2026) Table 56. Global Coagulation Factor II Monoclonal Antibody Market Average Price (US$/unit) by Region (2027-2032) Table 57. Global Coagulation Factor II Monoclonal Antibody Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global Coagulation Factor II Monoclonal Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Coagulation Factor II Monoclonal Antibody Sales by Country (2021-2026) & (k units) Table 60. Global Coagulation Factor II Monoclonal Antibody Sales Market Share by Country (2021-2026) Table 61. Global Coagulation Factor II Monoclonal Antibody Sales by Country (2027-2032) & (k units) Table 62. Global Coagulation Factor II Monoclonal Antibody Sales Market Share by Country (2027-2032) Table 63. Global Coagulation Factor II Monoclonal Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Coagulation Factor II Monoclonal Antibody Sales Value Market Share by Country (2021-2026) Table 65. Global Coagulation Factor II Monoclonal Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Coagulation Factor II Monoclonal Antibody Sales Value Market Share by Country (2027-2032) Table 67. ​​Abcam Company Information Table 68. ​​Abcam Business Overview Table 69. ​​Abcam Coagulation Factor II Monoclonal Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. ​​Abcam Coagulation Factor II Monoclonal Antibody Product Portfolio Table 71. ​​Abcam Recent Development Table 72. Abbexa Company Information Table 73. Abbexa Business Overview Table 74. Abbexa Coagulation Factor II Monoclonal Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Abbexa Coagulation Factor II Monoclonal Antibody Product Portfolio Table 76. Abbexa Recent Development Table 77. Arigo Biolaboratories Corp. Company Information Table 78. Arigo Biolaboratories Corp. Business Overview Table 79. Arigo Biolaboratories Corp. Coagulation Factor II Monoclonal Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Arigo Biolaboratories Corp. Coagulation Factor II Monoclonal Antibody Product Portfolio Table 81. Arigo Biolaboratories Corp. Recent Development Table 82. Assay Genie Company Information Table 83. Assay Genie Business Overview Table 84. Assay Genie Coagulation Factor II Monoclonal Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Assay Genie Coagulation Factor II Monoclonal Antibody Product Portfolio Table 86. Assay Genie Recent Development Table 87. Biorbyt Company Information Table 88. Biorbyt Business Overview Table 89. Biorbyt Coagulation Factor II Monoclonal Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Biorbyt Coagulation Factor II Monoclonal Antibody Product Portfolio Table 91. Biorbyt Recent Development Table 92. Bio-Techne Company Information Table 93. Bio-Techne Business Overview Table 94. Bio-Techne Coagulation Factor II Monoclonal Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Bio-Techne Coagulation Factor II Monoclonal Antibody Product Portfolio Table 96. Bio-Techne Recent Development Table 97. Cell Signaling Technology, Inc. Company Information Table 98. Cell Signaling Technology, Inc. Business Overview Table 99. Cell Signaling Technology, Inc. Coagulation Factor II Monoclonal Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Cell Signaling Technology, Inc. Coagulation Factor II Monoclonal Antibody Product Portfolio Table 101. Cell Signaling Technology, Inc. Recent Development Table 102. Creative Biolabs Company Information Table 103. Creative Biolabs Business Overview Table 104. Creative Biolabs Coagulation Factor II Monoclonal Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Creative Biolabs Coagulation Factor II Monoclonal Antibody Product Portfolio Table 106. Creative Biolabs Recent Development Table 107. GeneTex Company Information Table 108. GeneTex Business Overview Table 109. GeneTex Coagulation Factor II Monoclonal Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. GeneTex Coagulation Factor II Monoclonal Antibody Product Portfolio Table 111. GeneTex Recent Development Table 112. LifeSpan BioSciences, Inc Company Information Table 113. LifeSpan BioSciences, Inc Business Overview Table 114. LifeSpan BioSciences, Inc Coagulation Factor II Monoclonal Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. LifeSpan BioSciences, Inc Coagulation Factor II Monoclonal Antibody Product Portfolio Table 116. LifeSpan BioSciences, Inc Recent Development Table 117. MyBiosource, Inc. Company Information Table 118. MyBiosource, Inc. Business Overview Table 119. MyBiosource, Inc. Coagulation Factor II Monoclonal Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. MyBiosource, Inc. Coagulation Factor II Monoclonal Antibody Product Portfolio Table 121. MyBiosource, Inc. Recent Development Table 122. OriGene Technologies, Inc. Company Information Table 123. OriGene Technologies, Inc. Business Overview Table 124. OriGene Technologies, Inc. Coagulation Factor II Monoclonal Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. OriGene Technologies, Inc. Coagulation Factor II Monoclonal Antibody Product Portfolio Table 126. OriGene Technologies, Inc. Recent Development Table 127. RayBiotech, Inc. Company Information Table 128. RayBiotech, Inc. Business Overview Table 129. RayBiotech, Inc. Coagulation Factor II Monoclonal Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 130. RayBiotech, Inc. Coagulation Factor II Monoclonal Antibody Product Portfolio Table 131. RayBiotech, Inc. Recent Development Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Coagulation Factor II Monoclonal Antibody Distributors List Table 135. Coagulation Factor II Monoclonal Antibody Customers List Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. Coagulation Factor II Monoclonal Antibody Product Image Figure 2. Global Coagulation Factor II Monoclonal Antibody Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Coagulation Factor II Monoclonal Antibody Sales Value (2021-2032) & (US$ Million) Figure 4. Global Coagulation Factor II Monoclonal Antibody Sales (2021-2032) & (k units) Figure 5. Global Coagulation Factor II Monoclonal Antibody Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Coagulation Factor II Monoclonal Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Recombinant Image Figure 10. Non-recombinant Image Figure 11. Global Coagulation Factor II Monoclonal Antibody Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Coagulation Factor II Monoclonal Antibody Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Coagulation Factor II Monoclonal Antibody Sales Volume Share by Type (2021-2032) Figure 14. Global Coagulation Factor II Monoclonal Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Coagulation Factor II Monoclonal Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Coagulation Factor II Monoclonal Antibody Sales Value Share by Type (2021-2032) Figure 17. Immunofluorescence Image Figure 18. Immunoprecipitation Image Figure 19. ELISA Image Figure 20. Flow Cytometry Image Figure 21. Western Blot Image Figure 22. Other Image Figure 23. Global Coagulation Factor II Monoclonal Antibody Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Coagulation Factor II Monoclonal Antibody Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Coagulation Factor II Monoclonal Antibody Sales Volume Share by Application (2021-2032) Figure 26. Global Coagulation Factor II Monoclonal Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Coagulation Factor II Monoclonal Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Coagulation Factor II Monoclonal Antibody Sales Value Share by Application (2021-2032) Figure 29. Global Coagulation Factor II Monoclonal Antibody Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global Coagulation Factor II Monoclonal Antibody Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Coagulation Factor II Monoclonal Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Coagulation Factor II Monoclonal Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Coagulation Factor II Monoclonal Antibody Sales Value (2021-2032) & (US$ Million) Figure 34. North America Coagulation Factor II Monoclonal Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Coagulation Factor II Monoclonal Antibody Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Coagulation Factor II Monoclonal Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Coagulation Factor II Monoclonal Antibody Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Coagulation Factor II Monoclonal Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Coagulation Factor II Monoclonal Antibody Sales Value (2021-2032) & (US$ Million) Figure 40. South America Coagulation Factor II Monoclonal Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Coagulation Factor II Monoclonal Antibody Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Coagulation Factor II Monoclonal Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Coagulation Factor II Monoclonal Antibody Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Coagulation Factor II Monoclonal Antibody Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant
  • Non-recombinant
Applications
  • Immunofluorescence
  • Immunoprecipitation
  • ELISA
  • Flow Cytometry
  • Western Blot
  • Other
Companies covered
  • ​​Abcam
  • Abbexa
  • Arigo Biolaboratories Corp.
  • Assay Genie
  • Biorbyt
  • Bio-Techne
  • Cell Signaling Technology, Inc.
  • Creative Biolabs
  • GeneTex
  • LifeSpan BioSciences, Inc
  • MyBiosource, Inc.
  • OriGene Technologies, Inc.
  • RayBiotech, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Coagulation Factor II Monoclonal Antibody Sales Value (2021-2032)
  4. 1.2.2 Global Coagulation Factor II Monoclonal Antibody Sales Volume (2021-2032)
  5. 1.2.3 Global Coagulation Factor II Monoclonal Antibody Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Coagulation Factor II Monoclonal Antibody Market Dynamics
  1. 2.1 Coagulation Factor II Monoclonal Antibody Industry Trends
  2. 2.2 Coagulation Factor II Monoclonal Antibody Industry Drivers
  3. 2.3 Coagulation Factor II Monoclonal Antibody Industry Opportunities and Challenges
  4. 2.4 Coagulation Factor II Monoclonal Antibody Industry Restraints
3 Coagulation Factor II Monoclonal Antibody Market by Company
  1. 3.1 Global Coagulation Factor II Monoclonal Antibody Company Revenue Ranking in 2025
  2. 3.2 Global Coagulation Factor II Monoclonal Antibody Revenue by Company (2021-2026)
  3. 3.3 Global Coagulation Factor II Monoclonal Antibody Sales Volume by Company (2021-2026)
  4. 3.4 Global Coagulation Factor II Monoclonal Antibody Average Price by Company (2021-2026)
  5. 3.5 Global Coagulation Factor II Monoclonal Antibody Company Ranking (2024-2026)
  6. 3.6 Global Coagulation Factor II Monoclonal Antibody Company Manufacturing Base and Headquarters
  7. 3.7 Global Coagulation Factor II Monoclonal Antibody Company Product Type and Application
  8. 3.8 Global Coagulation Factor II Monoclonal Antibody Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Coagulation Factor II Monoclonal Antibody Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Coagulation Factor II Monoclonal Antibody Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Coagulation Factor II Monoclonal Antibody Market by Type
  1. 4.1 Coagulation Factor II Monoclonal Antibody Type Introduction
  2. 4.1.1 Recombinant
  3. 4.1.2 Non-recombinant
  4. 4.2 Global Coagulation Factor II Monoclonal Antibody Sales Volume by Type
  5. 4.2.1 Global Coagulation Factor II Monoclonal Antibody Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Coagulation Factor II Monoclonal Antibody Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Coagulation Factor II Monoclonal Antibody Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Coagulation Factor II Monoclonal Antibody Sales Value by Type
  9. 4.3.1 Global Coagulation Factor II Monoclonal Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Coagulation Factor II Monoclonal Antibody Sales Value by Type (2021-2032)
  11. 4.3.3 Global Coagulation Factor II Monoclonal Antibody Sales Value Share by Type (2021-2032)
5 Coagulation Factor II Monoclonal Antibody Market by Application
  1. 5.1 Coagulation Factor II Monoclonal Antibody Application Introduction
  2. 5.1.1 Immunofluorescence
  3. 5.1.2 Immunoprecipitation
  4. 5.1.3 ELISA
  5. 5.1.4 Flow Cytometry
  6. 5.1.5 Western Blot
  7. 5.1.6 Other
  8. 5.2 Global Coagulation Factor II Monoclonal Antibody Sales Volume by Application
  9. 5.2.1 Global Coagulation Factor II Monoclonal Antibody Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Coagulation Factor II Monoclonal Antibody Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Coagulation Factor II Monoclonal Antibody Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Coagulation Factor II Monoclonal Antibody Sales Value by Application
  13. 5.3.1 Global Coagulation Factor II Monoclonal Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Coagulation Factor II Monoclonal Antibody Sales Value by Application (2021-2032)
  15. 5.3.3 Global Coagulation Factor II Monoclonal Antibody Sales Value Share by Application (2021-2032)
6 Coagulation Factor II Monoclonal Antibody Regional Sales and Value Analysis
  1. 6.1 Global Coagulation Factor II Monoclonal Antibody Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Coagulation Factor II Monoclonal Antibody Sales by Region (2021-2032)
  3. 6.2.1 Global Coagulation Factor II Monoclonal Antibody Sales by Region: 2021-2026
  4. 6.2.2 Global Coagulation Factor II Monoclonal Antibody Sales by Region (2027-2032)
  5. 6.3 Global Coagulation Factor II Monoclonal Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Coagulation Factor II Monoclonal Antibody Sales Value by Region (2021-2032)
  7. 6.4.1 Global Coagulation Factor II Monoclonal Antibody Sales Value by Region: 2021-2026
  8. 6.4.2 Global Coagulation Factor II Monoclonal Antibody Sales Value by Region (2027-2032)
  9. 6.5 Global Coagulation Factor II Monoclonal Antibody Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Coagulation Factor II Monoclonal Antibody Sales Value (2021-2032)
  12. 6.6.2 North America Coagulation Factor II Monoclonal Antibody Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Coagulation Factor II Monoclonal Antibody Sales Value (2021-2032)
  15. 6.7.2 Europe Coagulation Factor II Monoclonal Antibody Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Coagulation Factor II Monoclonal Antibody Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Coagulation Factor II Monoclonal Antibody Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Coagulation Factor II Monoclonal Antibody Sales Value (2021-2032)
  21. 6.9.2 South America Coagulation Factor II Monoclonal Antibody Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Coagulation Factor II Monoclonal Antibody Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Coagulation Factor II Monoclonal Antibody Sales Value Share by Country, 2025 VS 2032
7 Coagulation Factor II Monoclonal Antibody Country-level Sales and Value Analysis
  1. 7.1 Global Coagulation Factor II Monoclonal Antibody Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Coagulation Factor II Monoclonal Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Coagulation Factor II Monoclonal Antibody Sales by Country (2021-2032)
  4. 7.3.1 Global Coagulation Factor II Monoclonal Antibody Sales by Country (2021-2026)
  5. 7.3.2 Global Coagulation Factor II Monoclonal Antibody Sales by Country (2027-2032)
  6. 7.4 Global Coagulation Factor II Monoclonal Antibody Sales Value by Country (2021-2032)
  7. 7.4.1 Global Coagulation Factor II Monoclonal Antibody Sales Value by Country (2021-2026)
  8. 7.4.2 Global Coagulation Factor II Monoclonal Antibody Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Coagulation Factor II Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Coagulation Factor II Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Coagulation Factor II Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ​​Abcam
  2. 8.1.1 ​​Abcam Company Information
  3. 8.1.2 ​​Abcam Business Overview
  4. 8.1.3 ​​Abcam Coagulation Factor II Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 ​​Abcam Coagulation Factor II Monoclonal Antibody Product Portfolio
  6. 8.1.5 ​​Abcam Recent Developments
  7. 8.2 Abbexa
  8. 8.2.1 Abbexa Company Information
  9. 8.2.2 Abbexa Business Overview
  10. 8.2.3 Abbexa Coagulation Factor II Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Abbexa Coagulation Factor II Monoclonal Antibody Product Portfolio
  12. 8.2.5 Abbexa Recent Developments
  13. 8.3 Arigo Biolaboratories Corp.
  14. 8.3.1 Arigo Biolaboratories Corp. Company Information
  15. 8.3.2 Arigo Biolaboratories Corp. Business Overview
  16. 8.3.3 Arigo Biolaboratories Corp. Coagulation Factor II Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Arigo Biolaboratories Corp. Coagulation Factor II Monoclonal Antibody Product Portfolio
  18. 8.3.5 Arigo Biolaboratories Corp. Recent Developments
  19. 8.4 Assay Genie
  20. 8.4.1 Assay Genie Company Information
  21. 8.4.2 Assay Genie Business Overview
  22. 8.4.3 Assay Genie Coagulation Factor II Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Assay Genie Coagulation Factor II Monoclonal Antibody Product Portfolio
  24. 8.4.5 Assay Genie Recent Developments
  25. 8.5 Biorbyt
  26. 8.5.1 Biorbyt Company Information
  27. 8.5.2 Biorbyt Business Overview
  28. 8.5.3 Biorbyt Coagulation Factor II Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Biorbyt Coagulation Factor II Monoclonal Antibody Product Portfolio
  30. 8.5.5 Biorbyt Recent Developments
  31. 8.6 Bio-Techne
  32. 8.6.1 Bio-Techne Company Information
  33. 8.6.2 Bio-Techne Business Overview
  34. 8.6.3 Bio-Techne Coagulation Factor II Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bio-Techne Coagulation Factor II Monoclonal Antibody Product Portfolio
  36. 8.6.5 Bio-Techne Recent Developments
  37. 8.7 Cell Signaling Technology, Inc.
  38. 8.7.1 Cell Signaling Technology, Inc. Company Information
  39. 8.7.2 Cell Signaling Technology, Inc. Business Overview
  40. 8.7.3 Cell Signaling Technology, Inc. Coagulation Factor II Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Cell Signaling Technology, Inc. Coagulation Factor II Monoclonal Antibody Product Portfolio
  42. 8.7.5 Cell Signaling Technology, Inc. Recent Developments
  43. 8.8 Creative Biolabs
  44. 8.8.1 Creative Biolabs Company Information
  45. 8.8.2 Creative Biolabs Business Overview
  46. 8.8.3 Creative Biolabs Coagulation Factor II Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Creative Biolabs Coagulation Factor II Monoclonal Antibody Product Portfolio
  48. 8.8.5 Creative Biolabs Recent Developments
  49. 8.9 GeneTex
  50. 8.9.1 GeneTex Company Information
  51. 8.9.2 GeneTex Business Overview
  52. 8.9.3 GeneTex Coagulation Factor II Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GeneTex Coagulation Factor II Monoclonal Antibody Product Portfolio
  54. 8.9.5 GeneTex Recent Developments
  55. 8.10 LifeSpan BioSciences, Inc
  56. 8.10.1 LifeSpan BioSciences, Inc Company Information
  57. 8.10.2 LifeSpan BioSciences, Inc Business Overview
  58. 8.10.3 LifeSpan BioSciences, Inc Coagulation Factor II Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 LifeSpan BioSciences, Inc Coagulation Factor II Monoclonal Antibody Product Portfolio
  60. 8.10.5 LifeSpan BioSciences, Inc Recent Developments
  61. 8.11 MyBiosource, Inc.
  62. 8.11.1 MyBiosource, Inc. Company Information
  63. 8.11.2 MyBiosource, Inc. Business Overview
  64. 8.11.3 MyBiosource, Inc. Coagulation Factor II Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 MyBiosource, Inc. Coagulation Factor II Monoclonal Antibody Product Portfolio
  66. 8.11.5 MyBiosource, Inc. Recent Developments
  67. 8.12 OriGene Technologies, Inc.
  68. 8.12.1 OriGene Technologies, Inc. Company Information
  69. 8.12.2 OriGene Technologies, Inc. Business Overview
  70. 8.12.3 OriGene Technologies, Inc. Coagulation Factor II Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 OriGene Technologies, Inc. Coagulation Factor II Monoclonal Antibody Product Portfolio
  72. 8.12.5 OriGene Technologies, Inc. Recent Developments
  73. 8.13 RayBiotech, Inc.
  74. 8.13.1 RayBiotech, Inc. Company Information
  75. 8.13.2 RayBiotech, Inc. Business Overview
  76. 8.13.3 RayBiotech, Inc. Coagulation Factor II Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 RayBiotech, Inc. Coagulation Factor II Monoclonal Antibody Product Portfolio
  78. 8.13.5 RayBiotech, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Coagulation Factor II Monoclonal Antibody Value Chain Analysis
  2. 9.1.1 Coagulation Factor II Monoclonal Antibody Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Coagulation Factor II Monoclonal Antibody Sales Mode & Process
  6. 9.2 Coagulation Factor II Monoclonal Antibody Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Coagulation Factor II Monoclonal Antibody Distributors
  9. 9.2.3 Coagulation Factor II Monoclonal Antibody Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst